3.5 billion yuan transformation medicine
Achievements in recent years (unit: 10,000 yuan)
The Yangtze river embellish is an elevator system component manufacturer, mainly engaged in the development, production, sales and service of elevator guide system components. In 2016, the company realized revenue of 21.15 billion yuan, an increase of over 1 billion yuan compared with last year, with a growth rate of 98.65%. Net profit was 299 million yuan, up 604.48 percent year-on-year. The net profit attributable to the parent company was 1.60 billion yuan, up 271.78% from the previous year.
According to the data, in 2015, the Yangtze river embellish launched a major asset reorganization, and has applied for temporary suspensions many times; In January 2016, the Yangtze river embellish to offer a formal surfaced, at 14.31 yuan/company issued 223 million shares, and cash 300 million yuan, a total of 3.5 billion yuan, the acquisition of the Yangtze river rt medical investment co., LTD. 100% stake in zhangjiagang free trade zone. At the same time, with 16.62 yuan/share issuing shares, the supporting fund will not exceed 1.2 billion yuan and invest in medical projects.
Building a new business: the pharmaceutical business is getting more than 1 billion a year
The composition of the operating income of the Yangtze river (unit: yuan)
At present, the main business covers the original elevator rail industry and the new medical business. The original elevator guide line will be operated in the platform of changjiang runout (zhangjiagang) machinery co., LTD. Yangtze river rt zhangjiagang free trade zone investment pharmaceutical co., LTD., will serve as a medical operation platform of the plates, and listed companies will be renamed the Yangtze rt pharmaceutical co., LTD. And as a management platform to operate. It is worth mentioning that the company through the Yangtze river pharmaceutical investment holding hainan sea spirit chemical & pharmaceutical co., LTD., the new game pharmaceutical co., LTD., as well as the best (Asia) medical co., LTD. 100% stake in three high quality pharmaceutical enterprises, covering anti-infection drugs production and sales of new basic link of pharmaceutical manufacturing operations. This time, the Yangtze river embellish will purchase pharmaceutical assets through controlling shareholders and complete asset injection. It aims to build a medical capital platform for the company in a short period of time to build a new main industry.
From the point of incomes, the growth of the Yangtze river rt thanks to purchase the above three pharmaceutical enterprises, the company in 2016 medical revenue from "zero" a breakthrough 1 billion yuan, 1.157 billion yuan, and more than 958 million yuan of elevator guide rail, to become the leading industry of the Yangtze river rt mart.
The future: the elevator guide line business is stable development, the medicine business develops rapidly
In 2017, the Yangtze river rundown will accelerate the transformation of the big health industry, and continue to promote the transformation of the big health industry through integration of resources and merger and acquisition. To realize the stable development of elevator guide business and rapid development of pharmaceutical business.
For new pharmaceutical business, the Yangtze river rt mart is a focus on oxygen to cefazolin sodium and cephalosporin him totally two main product procurement and sales, sales link in addition to the previous agent, to strengthen the direct sales of major hospital, to ensure that the volumes are going. Second, in the existing 100 batches, excavate good varieties, combine the construction of fund-raising projects, accelerate the formation of production capacity and sales, and strive to form new growth points. Third, we will carry out the follow-up work of the products of "stomach quadruple" and "luriconazole", and reserve the future development. Fourth, we will strengthen the research and development and reserve of new products, and accelerate the development of products such as microspheres, by working with external research and development agencies. We will work together to find the right medical products for the rapid development of the pharmaceutical business. |
